Accessibility and potency of uterotonic drugs purchased by simulated clients in four districts in India

BMC Pregnancy and Childbirth

Volumn 14, Issue 1, 2014, Pages

  Stanton, Cynthia ^a   Nand, Deepak Nitya ^b   Koski, Alissa ^a   Mirzabagi, Ellie ^a   Brooke, Steve ^c   Grady, Breanne ^c   Mullany, Luke C ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b PATH   (India)

^c PATH   (United States)

Author keywords

India; Medicines quality; Methylergometrine; Oxytocin; Potency; Uterotonics

Indexed keywords

METHYLERGOMETRINE; MISOPROSTOL; OXYTOCIN; VALETHAMATE BROMIDE; OXYTOCIC AGENT; QUATERNARY AMMONIUM DERIVATIVE;

AMPOULE; ARTICLE; DRUG MONITORING; DRUG POTENCY; DRUG QUALITY; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; DRUG USE; HUMAN; INDIA; ORGANIZATION AND MANAGEMENT; PHARMACEUTICAL CARE; PHARMACY; POSTPARTUM HEMORRHAGE; PRESCRIPTION; PUERPERIUM; SIMULATION; FEMALE; PREGNANCY; STANDARDS; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

FEMALE; HUMANS; INDIA; METHYLERGONOVINE; MISOPROSTOL; OXYTOCICS; OXYTOCIN; PHARMACIES; POSTPARTUM HEMORRHAGE; PREGNANCY; PRIVATE SECTOR; QUATERNARY AMMONIUM COMPOUNDS;

EID: 84925382497     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/s12884-014-0386-y     Document Type: Article

References (35)

1. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF: WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367(9516):1066-1074.
2. Office of Registrar General India: Special Bulletin on Maternal Mortality in India 2007-2009. New Delhi: 2011. http://ghdx.healthdata.org/record/india-srs-special-bulletin-maternal-mortality-2007-2009.
3. WHO: WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: Department of Reproductive Health, World Health Organization; 2012.
4. Government of India: Guidelines for antenatal care and skilled attendance at birth by ANMs and LHVs. New Delhi: Ministry of Health and Family Welfare, Department of Family Welfare, Division of Maternal Health; 2005:25-29.
5. Government of India: Guidelines for Pregnancy Care and Management of Common Obstetric Complications by Medical Officers. New Delhi: Ministry of Health and Family Welfare, Department of Family Welfare, Division of Maternal Health; 2005:29.
6. WHO: Comparative Table of Medicines on the WHO Essential Medicines List from 1977-2011. Geneva: World Health Organization; 2013.
7. Partnership for Maternal, Newborn and Child Health: A Global Review of the Key Interventions related to Reproductive, Maternal, Newborn and Child Health (RMNCH). Geneva: 2011. http://www.who.int/pmnch/knowledge/publications/201112_essential_interventions/en/.
8. United Nations: United Nations Commission on Life-Saving Commodities for Women and Children; Commissioner's Report 2012. New York: United Nations; 2012. http://www.unfpa.org/webdav/site/global/shared/images/publications/2012/Final%20UN%20Commission%20Report_14sept2012.pdf.
9. Bate R, Tren R, Mooney L, Hess K, Mitra B, Debroy B, Attaran A: Pilot study of essential drug quality in two major cities in India. PLoS One 2009, 4:e6003.
10. Newton PN, Green MD, Fernàndez FM, Day NPJ, White NJ: Counterfeit anti-infective drugs. Lancet Infect Dis 2006, 6:602-613.
11. Lancet: Counterfeit drugs: a growing global threat. Lancet 2012, 379(9817):685.
12. Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, Pinel J: Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008, 13:1062-1072.
13. Newton PN, Lee SJ, Goodman C, Fernàndez FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJM, Kokwaro GO, Lindegardh N, Lukulay P, White LJ, Day NP, Green MD, White NJ: Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med 2009, 6:252-257.
14. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Guerin PJ, White NJ: The primacy of public health considerations in defining poor quality medicines. PLoS Med 2011, 8:e1001139.
15. Delepierre A, Gayot A, Carpentier A: Update on counterfeit antibiotics worldwide: public health risks. Med Mal Infect 2012, 42:247-255.
16. The Global Fund to Fight AIDS Tuberculosis and Malaria: Quality Assurance of Pharmaceutical Products. 2012. http://www.theglobalfund.org/en/procurement/quality/pharmaceutical/.
17. WHO: Expanded Programme on Immunization. Geneva: World Health Organization; 2014. http://www.who.int/immunization/quality_safety/en/.
18. WHO: WHO Recommendations for the Prevention of Postpartum Hemorrhage. Geneva: World Health Organization; 2007.
19. Hogerzeil HV, Walker GJA, De Goeje MJ: Stability of Injectable Oxytocics in Tropical Climates: Results of Field Surveys and Simulation Studies on Ergometrine, Methylergometrine and Oxytocin. Geneva: WHO Action Programme on Essential Drugs; 1993.
20. de Groot AN, Hector YA, Vree TB, Van Dongen PW: Oxytocin and desamino-oxytocin tablets are not stable under simulated tropical conditions. J Clin Pharm Ther 1995, 20:115-119.
21. Hogerzeil HV, Battersby A, Srdanovic V, Stjernstrom NE: Stability of essential drugs during shipment to the tropics. BMJ 1992, 304:210-212.
22. Nazerali H, Hogerzeil H: The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study. BMJ 1998, 317:512-513.
23. Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S: Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana. BMJ Open 2012, 2(3):e000431. doi:10.1136/bmjopen-2011-000431.
24. Karikari Boateng E: Post-Market Quality Surveillance Project Maternal Health Care Products on the Ghanaian Market. Accra, Ghana: Ghana Food and Drugs Authority; 2013.
25. Seear M, Ghandhi D, Carr R, Dayal A, Raghavan D, Sharma N: The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India. J Clin Pharm Ther 2011, 36:488-495.
26. Babu TA: Valethamate bromide: conflicting evidence and continuing use. J Pharmacol Pharmacother 2010, 1:120.
27. Madhu CM, Mahavarkar S, Bhave S: A randomised controlled study comparing Drotaverine hydrochloride and Valethamate bromide in the augmentation of labour. Arch Gynecol Obstet 2010, 282:11-15.
28. International Institute for Population Studies: National Family Health Survey (NFHS - 3) 2005-2006, India, Volume 1. Mumbai, India: International Institute for Population Studies; 2007.
29. Government of India: Census of India 2011; Provisional Results Uttar Pradesh. New Delhi, India: Ministry of Home Affairs, Office of the Registrar General and Census Commissioner; 2011.
30. Government of India: Census of India 2011; Provisional Results Karnataka. New Delhi, India: Ministry of Home Affairs, Office of the Registrar General and Census Commissioner; 2011.
31. International Institute for Population Studies: District Level Household and Facility Survey (DLHS-3), 2007-2008: India: Key Indicators: States and Districts. Mumbai, India: International Institute for Population Studies; 2010.
32. Brhlikova P, Jeffery P, Bhatia GP, Khurana S: Intraparum Oxytocin (Mis)Use in South Asia. J Health Stud 2009, 11:33-50.
33. Jeffery P, Das A, Dasgupta J, Jeffery R: Unmonitored intrapartum oxytocin use in home deliveries: evidence from Uttar Pradesh, India. Reprod Health Matters 2007, 15:172-178.
34. Stanton C, Deepak NN, Mallapur AA, Katageri GM, Mullany LC, Koski A, Mirzabagi E: Direct Observation of uterotonic drug use at public health facility-based deliveries in four districts in India. Int J Gynaecol Obstet 2014, 127(1):25-30.
35. John Snow Incorporated: Logistics Fact Sheet for Quality Control of Drugs, German Pharma Health Fund Mini-lab. Arlington, Virginia: John Snow, Incorporated; 2006.